<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.2d1 20170631//EN" "JATS-journalpublishing1.dtd">
<ArticleSet>
<Article>
<Journal>
<PublisherName>isfcppharmaspire</PublisherName>
<JournalTitle>Pharmaspire</JournalTitle>
<PISSN>C</PISSN>
<EISSN>o</EISSN>
<Volume-Issue>Volume 13, Issue 4 </Volume-Issue>
<PartNumber/>
<IssueTopic>Multidisciplinary</IssueTopic>
<IssueLanguage>English</IssueLanguage>
<Season>October - December, 2021</Season>
<SpecialIssue>N</SpecialIssue>
<SupplementaryIssue>N</SupplementaryIssue>
<IssueOA>Y</IssueOA>
<PubDate>
<Year>2022</Year>
<Month>06</Month>
<Day>2</Day>
</PubDate>
<ArticleType>Pharmaceutics</ArticleType>
<ArticleTitle>Molecular docking studies of curcumin with __ampersandsignbeta;-cyclodextrins to investigate pre-formulation perspective to overcome bioavailability problems</ArticleTitle>
<SubTitle/>
<ArticleLanguage>English</ArticleLanguage>
<ArticleOA>Y</ArticleOA>
<FirstPage>207</FirstPage>
<LastPage>210</LastPage>
<AuthorList>
<Author>
<FirstName>Rajib</FirstName>
<LastName>Das</LastName>
<AuthorLanguage>English</AuthorLanguage>
<Affiliation/>
<CorrespondingAuthor>N</CorrespondingAuthor>
<ORCID/>
<FirstName>Kankan</FirstName>
<LastName>Roy</LastName>
<AuthorLanguage>English</AuthorLanguage>
<Affiliation/>
<CorrespondingAuthor>Y</CorrespondingAuthor>
<ORCID/>
<FirstName>Ankit Kumar</FirstName>
<LastName>Rai</LastName>
<AuthorLanguage>English</AuthorLanguage>
<Affiliation/>
<CorrespondingAuthor>Y</CorrespondingAuthor>
<ORCID/>
<FirstName>Sant Kumar</FirstName>
<LastName>Verma</LastName>
<AuthorLanguage>English</AuthorLanguage>
<Affiliation/>
<CorrespondingAuthor>Y</CorrespondingAuthor>
<ORCID/>
</Author>
</AuthorList>
<DOI/>
<Abstract>__ampersandsignbeta;-cyclodextrin (__ampersandsignbeta;-CD) are used to form host-guest inclusion complexes with poorly water-soluble drugs in solution or a solid-state. Inclusion complexes formed with a host-guest molecule may exhibit improved chemical or biological properties compared to the host molecule alone. Such inclusion may improve aqueous solubility, dissolution, and bioavailability. However, the use of CDs is limited in some cases because it is very difficult, to identify the most suitable CD as a host complexing agent for a particular drug, to map whether the guest molecule is fitted partially or completely within the core of CD, and to predict the classic stereo-structure of the polymer and the forces between host and guest complex. Owing to low aqueous solubility of __ampersandsignbeta;-CD (18 g/L), its higher water-soluble analogs such as hydroxypropyl, sulfobutyl ether (SE), and methyl __ampersandsignbeta;-CDs are most favored for complexation. In the present study, highest water-soluble __ampersandsignbeta;-CD, i.e., (SE __ampersandsignbeta;-CD, solubility ~700g/L g/L) was selected for in silico complexation studies with curcumin, compared to conventional __ampersandsignbeta;-CD, using molecular docking studies. The results of in silico affinity and interaction studies showed that SE __ampersandsignbeta;-CD has more affinity for curcumin compared to __ampersandsignbeta;-CD in terms of MolDock score. This computational study may be used as a guide for pre-formulation prospective of curcumin to overcome the solubility and bioavailability problems associated.</Abstract>
<AbstractLanguage>English</AbstractLanguage>
<Keywords>Curcumin, in silico complexation, molecular docking, sulfobutyl ether ?-cyclodextrin</Keywords>
<URLs>
<Abstract>https://isfcppharmaspire.com/ubijournal-v1copy/journals/abstract.php?article_id=13769&title=Molecular docking studies of curcumin with __ampersandsignbeta;-cyclodextrins to investigate pre-formulation perspective to overcome bioavailability problems</Abstract>
</URLs>
<References>
<ReferencesarticleTitle>References</ReferencesarticleTitle>
<ReferencesfirstPage>16</ReferencesfirstPage>
<ReferenceslastPage>19</ReferenceslastPage>
<References>Aggarwal BB, Kumar A, Bharti AC. Anticancer potential of curcumin: Preclinical and clinical studies. Anticancer Res 2003;23:363-98.
Payton F, Sandusky P, Alworth WL. NMR study of the solution structure of curcumin. J Nat Prod 2007;70:143-6.
Sharma OP. Antioxidant activity of curcumin and related compounds. Biochem Pharmacol 1976;25:1811-2.
Sugiyama Y, Kawakishi S, Osawa T. Involvement of the and;beta;-diketone moiety in the antioxidative mechanism of tetrahydrocurcumin. Biochem Pharmacol 1996;52:519-25.
Ruby AJ, Kuttan G, Babu KD, Rajasekharan KN, Kuttan R. Anti-tumour and antioxidant activity of natural curcuminoids. Cancer Lett 1995;94:79-83.
Srimal RC, Dhawan BN. Pharmacology of diferuloyl methane (curcumin), a non-steroidal anti-inflammatory agent. J Pharm Pharmacol 1973;25:447-52.
Mahady GB, Pendland SL, Yun G, Lu ZZ. Turmeric (Curcuma longa) and curcumin inhibit the growth of Helicobacter pylori, a group 1 carcinogen. Anticancer Res 2002;22:4179-81.
Jordan WC, Drew CR. Curcumin--a natural herb with anti-HIV activity. J Natl Med Assoc 1996;88:333.
Kim MK, Choi GJ, Lee HS. Fungicidal property of Curcuma longa L. Rhizomederived curcumin against phytopathogenic fungi in a greenhouse. J Agric Food Chem 2003;51:1578-81.
Reddy RC, Vatsala PG, Keshamouni VG, Padmanaban G, Rangarajan PN. Curcumin for malaria therapy. Biochem Biophys Res Commun 2005;326:472-4.
Kiso Y, Suzuki Y, Watanabe N, Oshima Y, Hikino H. Antihepatotoxic principles of Curcuma longa rhizomes. Planta Med 1983;49:185-7.
Kuttan R, Bhanumathy P, Nirmala K, George MC. Potential anticancer activity of turmeric (Curcuma longa). Cancer Lett 1985;29:197-202.
Venkatesan N. Curcumin attenuation of acute adriamycin myocardial toxicity in rats. Br J Pharmacol 1998;124:425-7.
Srivastava R, Dikshit M, Srimal RC, Dhawan BN. Anti-thrombotic effect of curcumin. Thromb Res 1985;40:413-7.
Venkatesan N, Punithavathi D, Arumugam V. Curcumin prevents adriamycin nephrotoxicity in rats. Br J Pharmacol 2000;129:231-4.
Dikshit M, Rastogi L, Shukla R, Srimal RC. Prevention of ischaemia-induced biochemical changes by curcumin and quinidine in the cat heart. Indian J Med Res 1995;101:31-5.
Nirmala C, Puvanakrishnan R. Effect of curcumin on certain lysosomal hydrolases in isoproterenol-induced myocardial infarction in rats. Biochem Pharmacol 1996;51:47-51.
Nirmala C, Puvanakrishnan R. Protective role of curcumin against isoproterenol induced myocardial infarction in rats. Mol Cell Biochem 1996;159:85-93.
Srinivasan M. Effect of curcumin on blood sugar as seen in a diabetic subject. Indian J Med Sci 1972;26:269-70.
Babu PS, Srinivasan K. Hypolipidemic action of curcumin, the active principle of turmeric (Curcuma longa) in streptozotocin induced diabetic rats. Mol Cell Biochem 1997;166:169-75.
Babu PS, Srinivasan K. Influence of dietary curcumin and cholesterol on the progression of experimentally induced diabetes in albino rat. Mol Cell Biochem 1995;152:13-21.
Deodhar SD, Sethi R, Srimal RC. Preliminary study on antirheumatic activity of curcumin (diferuloyl methane). Indian J Med Res 1980;71:632-4.
Arun N, Nalini N. Efficacy of turmeric on blood sugar and polyol pathway in diabetic albino rats. Plant Foods Hum Nutr 2002;57:41-52.
Qureshi S, Shah AH, Ageel AM. Toxicity studies on Alpinia galanga and Curcuma longa. Planta Med 1992;58:124-7.
Shankar TN, Shantha NV, Ramesh HP, Murthy IA, Murthy VS. Toxicity studies on turmeric (Curcuma longa): Acute toxicity studies in rats, guineapigs and monkeys. Indian J Exp Biol 1980;18:73-5.
Lao CD, Ruffin MT, Normolle D, Heath DD, Murray SI, Bailey JM, et al. Dose escalation of a curcuminoid formulation. BMC Complement Altern Med 2006;6:10.
Lao CD, Demierre MF, Sondak VK. Targeting events in melanoma carcinogenesis for the prevention of melanoma. Expert Rev Anticancer Ther 2006;6:1559-68.
Shoba G, Joy D, Joseph T, Majeed M, Rajendran R, Srinivas P. S. Influence of piperine on the pharmacokinetics of curcumin in animals and human volunteers. Planta Med 1998;64:353-6.
Cheng AL, Hsu CH, Lin JK, Hsu MM, Ho YF, Shen TS, et al. Phase I clinical trial of curcumin, a chemopreventive agent, in patients with high-risk or premalignant lesions. Anticancer Res 2001;21:2895-900.
Mihoub AB, Larue L, Moussaron A, Youssef Z, Colombeau L, Baros F, et al. Use of cyclodextrins in anticancer photodynamic therapy treatment. Molecules 2018;23:1936.</References>
</References>
</Journal>
</Article>
</ArticleSet>